Navigation Links
HeartWare International Reports Third Quarter Revenues of $7.5 Million
Date:11/4/2009

uted share, compared to a $19.8 million net loss, or a loss of $2.61 per basic and diluted share, in the prior year nine-month period. These figures include a $2.2 million (non-cash) charge recorded during the 2009 period associated with a change in the fair value of a derivative instrument embedded in the $20 million loan facility provided by Thoratec Corporation.

Godshall continued, "We are making the necessary investments in our operating infrastructure, staffing and clinical trials so as to lay the foundation for our continued growth."

The balance sheet was strengthened during the third quarter as a result of a $60 million private placement of common stock entered into in mid August 2009. At September 30, 2009 the balance sheet showed $31.4 million in cash and cash equivalents, with the outstanding $30.7 million of the $60 million private placement having been released from escrow to the Company following stockholder approval of the private placement on October 26, 2009.

The Company will host a conference call on Thursday, November 5, 2009 at 8:00 a.m. U.S. Eastern time (being 12:00 a.m. Australian Eastern Daylight Time between November 5 and 6, 2009) to discuss its third quarter results. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial +1-201-689-8471. Doug Godshall, Chief Executive Officer, President and Executive Director, and David McIntyre, Chief Financial Officer and Chief Operating Officer, will host the conference call.

A live web cast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Third Quarter and Nine Months Conference Call" under the section titled "Corporate Presentations" on the HOME page. A replay of the conference call will be available through the above weblink immediately f
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Increasing unnecessary regulations on drug plans could inflict higher ... medications through a managed drug plan, according to a ... Analysis Senior Fellow Devon Herrick. "The ... helps makes medications affordable," says Herrick. "Blatant protectionism through ... protections, but more often than not they are designed ...
(Date:4/20/2015)... -- Stand Up To Cancer (SU2C) and the American Cancer ... Team to attack the number one cancer killer in America, ... American Association for Cancer Research (AACR), Scientific Partner to SU2C. ... the United States will be diagnosed with ... from it, making lung cancer the leading cause of cancer ...
(Date:4/20/2015)... April 20, 2015 Eli Lilly and Company ... medicine ixekizumab was statistically superior to placebo in the ... demonstrated by the proportion of patients achieving an ACR ... represents a 20 percent reduction in disease signs and ... response criteria. During the 24-week, Phase 3 study, titled ...
Breaking Medicine Technology:Restrictive Drug Plan Regulations Will Hurt Patients 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... Richard Merkin, President and CEO of Heritage Provider Network, announced ... Health Prize, the world,s largest predictive modeling contest. ... Data 2.0 Conference in San Francisco, Dr. Merkin challenged innovators ... the $3 million prize saying, "We have an opportunity to ...
... Reportlinker.com announces that a new market research report ... Drug Delivery in Cancer - technologies, markets and ... Drug delivery remains a challenge in management ... cancer are being diagnosed worldwide each year and ...
Cached Medicine Technology:Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 2Heritage Provider Network Announces the Official Launch of the $3 million Dollar Heritage Health Prize 3Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies 2Reportlinker Adds Drug Delivery in Cancer - technologies, markets and companies 3
(Date:4/21/2015)... 2015 The Northeast Football Clinic (NEFC) ... Academy prep school in Byfield, MA. Applications are being ... boys entering grades 6-12. , The outstanding professional, college, ... fall coaching. , Offensive and defensive linemen ... these the most unsung positions on the field, the ...
(Date:4/21/2015)... Dr. Zain Kadri, a Beverly Hills plastic ... takes a close look at the rise of plastic surgery ... on both Dr. Kadri’s website and RedOrbit , is ... Age of the Selfie.” According to Dr. Kadri, who offers ... variety of A-list patients, the trend of taking selfies has ...
(Date:4/21/2015)... Sunnyvale, CA (PRWEB) April 21, 2015 ... research solutions for biopharmaceutical development, today announced that the ... at the University of Ottawa has acquired a Freeslate ... and Screening Pressure Reactor (SPR) to accelerate ... the High-Throughput Experimentation Facility where they will be available ...
(Date:4/21/2015)... Spring and summer are popular seasons to ... for the holidays or simply taking vacations. Deciding what ... can be a difficult choice. Pet-friendly accommodations are gaining ... becoming a more common option. Royal Flush Havanese ... pet-friendly accommodations a positive experience. , 1.) Firstly, it ...
(Date:4/21/2015)... This program provides physical therapists, ... occupational therapist assistants, teachers, and other school based ... children across the autism spectrum succeed in the ... Inc. , Used throughout the United ... yoga curriculum addresses learning and behavior issues across ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and The Northeast Football Clinic Announce 2015 Lineman/Linebacker Clinic Schedule 2Health News:Beverly Hills Plastic Surgery Expert Dr. Zain Kadri Releases Thought-Provoking New Infographic 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 3Health News:Royal Flush Havanese Announces 5 Tips for a Successful Stay in Pet-Friendly Accommodations 2Health News:Royal Flush Havanese Announces 5 Tips for a Successful Stay in Pet-Friendly Accommodations 3Health News:Royal Flush Havanese Announces 5 Tips for a Successful Stay in Pet-Friendly Accommodations 4Health News:ABC News Interviews Anne Buckley-Reen, Education Resources Inc. Faculty Member, on Yoga Therapy in the Classroom 2
... To Stay Happy and Healthy This WinterSAN JOSE, Calif., ... avoiding the "winter blues" is to set small goals, ... and exercising, for a well-rounded approach to life. This ... Day of the Year," January 26, 2009, designated by ...
... Strong Health and Economic Benefits of OTC Heartburn ... Consumer Healthcare Products Association (CHPA) and The Nielsen ... over-the-counter (OTC) heartburn medications and estimates that OTC ... each in office visits and medication costs annually. ...
... and print media; Mike Ditka, Frank Gifford, Michael Irvin, Tony Dorsett, ... Dickerson, Deacon Jones, Andre Reed, Tony Dorsett, Mercury Morris and many ... ... January 26, 2009 -- The Gridiron Greats Assistance Fund ...
... Inc. announces leading stem cell specialist Dr Nabil Dib, MD as ... President of the International Society for Cardiovascular Translational Research (ISCTR) and ... ... San Diego, CA (PRWEB) January 26, 2009 -- Stemedica Cell ...
... DNA solves another mystery when 57 year old Fred George discovered he ... fun and sometimes more seriously - accused his wife of having had ... rest of the family. , ... Pembroke, MA (PRWEB) January 26, 2009 ...
... injuries accounted for just 8 percent of all ... were relatively common in predominately male sports such ... (18 percent) and football (12 percent). Moreover, boys ... in soccer and baseball/softball. , ...
Cached Medicine News:Health News:Natural Solutions for the Most Depressing Day of the Year 2Health News:Natural Solutions for the Most Depressing Day of the Year 3Health News:Natural Solutions for the Most Depressing Day of the Year 4Health News:Natural Solutions for the Most Depressing Day of the Year 5Health News:CHPA, Nielsen: OTC Heartburn Therapy Saves Nearly $800 Million Annually, Vast Majority of OTC Heartburn Consumers Satisfied 2Health News:CHPA, Nielsen: OTC Heartburn Therapy Saves Nearly $800 Million Annually, Vast Majority of OTC Heartburn Consumers Satisfied 3Health News:100 NFL Legends Coming Together in Tampa During Super Bowl Week to Raise Awareness and Funds for Retired Players in Crisis 2Health News:100 NFL Legends Coming Together in Tampa During Super Bowl Week to Raise Awareness and Funds for Retired Players in Crisis 3Health News:100 NFL Legends Coming Together in Tampa During Super Bowl Week to Raise Awareness and Funds for Retired Players in Crisis 4Health News:Dr Nabil Dib Takes on Special Advisor Role to the Stemedica Board of Directors 2Health News:DNA Solves Switched at Birth Mystery ... After 57 Years 2Health News:DNA Solves Switched at Birth Mystery ... After 57 Years 3Health News:Shoulder injuries in US high school athletes occur more often in boys 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
Medicine Products: